CN104703980B - 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂 - Google Patents
属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂 Download PDFInfo
- Publication number
- CN104703980B CN104703980B CN201380051391.3A CN201380051391A CN104703980B CN 104703980 B CN104703980 B CN 104703980B CN 201380051391 A CN201380051391 A CN 201380051391A CN 104703980 B CN104703980 B CN 104703980B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- triazol
- methanone
- pyrrolidin
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 ***1CCCC1 Chemical compound ***1CCCC1 0.000 description 7
- ODVOWRJNPCEWAV-UHFFFAOYSA-N Cc1n[o]c(-c2cccc(C)c2C)n1 Chemical compound Cc1n[o]c(-c2cccc(C)c2C)n1 ODVOWRJNPCEWAV-UHFFFAOYSA-N 0.000 description 2
- JSIYGGNTVMFDHJ-UHFFFAOYSA-N C1C2=CCCCC12 Chemical compound C1C2=CCCCC12 JSIYGGNTVMFDHJ-UHFFFAOYSA-N 0.000 description 1
- JBIKZHQDYYUITF-UHFFFAOYSA-N CCOc(c(-c1nc(C)n[o]1)ccc1)c1F Chemical compound CCOc(c(-c1nc(C)n[o]1)ccc1)c1F JBIKZHQDYYUITF-UHFFFAOYSA-N 0.000 description 1
- ANLPGMDOOMJUBB-UHFFFAOYSA-N CCc(cccc1)c1-c1nc(C)n[o]1 Chemical compound CCc(cccc1)c1-c1nc(C)n[o]1 ANLPGMDOOMJUBB-UHFFFAOYSA-N 0.000 description 1
- BLWYXBNNBYXPPL-YFKPBYRVSA-N COC([C@H]1NCCC1)=O Chemical compound COC([C@H]1NCCC1)=O BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
- QJKDDLWNERCCHS-AWEZNQCLSA-N Cc1ccccc1-c1n[o]c([C@H](CCC2)N2C(c2ccc[s]2)=O)n1 Chemical compound Cc1ccccc1-c1n[o]c([C@H](CCC2)N2C(c2ccc[s]2)=O)n1 QJKDDLWNERCCHS-AWEZNQCLSA-N 0.000 description 1
- BNZFLGOJGSANMC-UHFFFAOYSA-N Cc1n[o]c(-c(cccc2)c2O)n1 Chemical compound Cc1n[o]c(-c(cccc2)c2O)n1 BNZFLGOJGSANMC-UHFFFAOYSA-N 0.000 description 1
- MKNOAAGSIDTHRR-UHFFFAOYSA-N Cc1n[o]c(-c(cccc2)c2OC(F)(F)F)n1 Chemical compound Cc1n[o]c(-c(cccc2)c2OC(F)(F)F)n1 MKNOAAGSIDTHRR-UHFFFAOYSA-N 0.000 description 1
- JCBIARRJDSXFCN-UHFFFAOYSA-N Cc1n[o]c(-c(cccc2F)c2OC)n1 Chemical compound Cc1n[o]c(-c(cccc2F)c2OC)n1 JCBIARRJDSXFCN-UHFFFAOYSA-N 0.000 description 1
- PFINTPRTYIEJPS-UHFFFAOYSA-N Cc1n[o]c(-c2c(C)c(F)ccc2)n1 Chemical compound Cc1n[o]c(-c2c(C)c(F)ccc2)n1 PFINTPRTYIEJPS-UHFFFAOYSA-N 0.000 description 1
- WZNGUFXYEZPOMT-UHFFFAOYSA-N Cc1n[o]c(-c2c(C)ccc(C)c2)n1 Chemical compound Cc1n[o]c(-c2c(C)ccc(C)c2)n1 WZNGUFXYEZPOMT-UHFFFAOYSA-N 0.000 description 1
- FQPSLPKSJDSTDP-UHFFFAOYSA-N Cc1n[o]c(-c2c(C)ccc(OC)c2)n1 Chemical compound Cc1n[o]c(-c2c(C)ccc(OC)c2)n1 FQPSLPKSJDSTDP-UHFFFAOYSA-N 0.000 description 1
- MMRSCHHIPAGBPU-UHFFFAOYSA-N Cc1n[o]c(-c2cc(OC)cc(C)c2)n1 Chemical compound Cc1n[o]c(-c2cc(OC)cc(C)c2)n1 MMRSCHHIPAGBPU-UHFFFAOYSA-N 0.000 description 1
- XFKKGPXRIBAUNM-UHFFFAOYSA-N Cc1n[o]c(-c2cccc(C)c2OC)n1 Chemical compound Cc1n[o]c(-c2cccc(C)c2OC)n1 XFKKGPXRIBAUNM-UHFFFAOYSA-N 0.000 description 1
- VXMNTRBHADWKDC-UHFFFAOYSA-N Cc1n[o]c(-c2cccc(OC)c2C)n1 Chemical compound Cc1n[o]c(-c2cccc(OC)c2C)n1 VXMNTRBHADWKDC-UHFFFAOYSA-N 0.000 description 1
- JITQGDWYQGMJGL-UHFFFAOYSA-N NC(C1CCCCCCCC1)NON Chemical compound NC(C1CCCCCCCC1)NON JITQGDWYQGMJGL-UHFFFAOYSA-N 0.000 description 1
- PFVHJRXWVNVUQZ-ZDUSSCGKSA-N O=C(c1ccc[s]1)N(CCC1)[C@@H]1c1nc(-c2cccc(Cl)c2)n[o]1 Chemical compound O=C(c1ccc[s]1)N(CCC1)[C@@H]1c1nc(-c2cccc(Cl)c2)n[o]1 PFVHJRXWVNVUQZ-ZDUSSCGKSA-N 0.000 description 1
- DOEGNOLRBNQMMM-ZDUSSCGKSA-N O=C(c1ccc[s]1)N(CCC1)[C@@H]1c1nc(-c2ccccc2)n[o]1 Chemical compound O=C(c1ccc[s]1)N(CCC1)[C@@H]1c1nc(-c2ccccc2)n[o]1 DOEGNOLRBNQMMM-ZDUSSCGKSA-N 0.000 description 1
- FCNHAWHRITXHDN-LBPRGKRZSA-N OC([C@H](CCC1)N1C(C1CCCCCCC1)=O)=O Chemical compound OC([C@H](CCC1)N1C(C1CCCCCCC1)=O)=O FCNHAWHRITXHDN-LBPRGKRZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12188019 | 2012-10-10 | ||
| EP12188019.9 | 2012-10-10 | ||
| EP13157809.8 | 2013-03-05 | ||
| EP13157809 | 2013-03-05 | ||
| PCT/IB2013/059233 WO2014057435A1 (en) | 2012-10-10 | 2013-10-09 | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104703980A CN104703980A (zh) | 2015-06-10 |
| CN104703980B true CN104703980B (zh) | 2017-09-22 |
Family
ID=49765598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380051391.3A Expired - Fee Related CN104703980B (zh) | 2012-10-10 | 2013-10-09 | 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9493446B2 (enExample) |
| EP (1) | EP2906553B1 (enExample) |
| JP (1) | JP6244365B2 (enExample) |
| KR (1) | KR102151288B1 (enExample) |
| CN (1) | CN104703980B (enExample) |
| AR (1) | AR092955A1 (enExample) |
| AU (1) | AU2013328301A1 (enExample) |
| BR (1) | BR112015007516A2 (enExample) |
| CA (1) | CA2885180C (enExample) |
| EA (1) | EA201500399A1 (enExample) |
| IL (1) | IL238052A0 (enExample) |
| MX (1) | MX2015004638A (enExample) |
| PH (1) | PH12015500627A1 (enExample) |
| SG (1) | SG11201502493XA (enExample) |
| TW (1) | TW201414727A (enExample) |
| WO (1) | WO2014057435A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101689093B1 (ko) | 2012-06-04 | 2016-12-22 | 액테리온 파마슈티칼 리미티드 | 벤즈이미다졸-프롤린 유도체 |
| WO2014141065A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
| ES2651475T3 (es) | 2013-12-03 | 2018-01-26 | Idorsia Pharmaceuticals Ltd | Forma cristalina de (S)-(2-(6-cloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2H-1,2,3-triazol-2-il)fenil)metanona y su uso como antagonistas del receptor de orexina |
| UA119151C2 (uk) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| MY179605A (en) | 2013-12-04 | 2020-11-11 | Idorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
| JP2017024990A (ja) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | オキサゾリジン及びオキサジナン誘導体 |
| US9938276B2 (en) | 2014-12-19 | 2018-04-10 | Merck Sharp & Dohme Corp. | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists |
| US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| US10370380B2 (en) | 2015-11-23 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof |
| CN106986859B (zh) * | 2016-01-20 | 2020-02-11 | 广东东阳光药业有限公司 | 吲哚衍生物及其用途 |
| CN110099898B (zh) | 2016-10-24 | 2023-07-25 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| KR20190108118A (ko) | 2017-01-06 | 2019-09-23 | 유마니티 테라퓨틱스, 인크. | 신경계 장애의 치료를 위한 방법 |
| EP3594202B1 (en) * | 2017-03-08 | 2021-08-11 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| CN108794454B (zh) * | 2017-04-27 | 2023-08-15 | 广东东阳光药业股份有限公司 | 一种咪唑环化合物的制备方法 |
| CA3059394C (en) * | 2017-05-03 | 2023-09-12 | Idorsia Pharmaceuticals Ltd | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives |
| WO2019018795A1 (en) * | 2017-07-20 | 2019-01-24 | Yumanity Therapeutics | COMPOUNDS AND USES THEREOF |
| EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
| CN111655260A (zh) * | 2017-10-26 | 2020-09-11 | 南方研究院 | 作为TGF-β抑制剂的噁二唑和噻二唑 |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| MA52365A (fr) | 2018-04-25 | 2021-03-03 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| EP3914593A4 (en) | 2019-01-24 | 2022-11-02 | Yumanity Therapeutics, Inc. | CONNECTIONS AND USES THEREOF |
| EP3917616B1 (en) | 2019-01-31 | 2025-06-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds and use thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| WO2022166768A1 (zh) * | 2021-02-02 | 2022-08-11 | 南京明德新药研发有限公司 | 四氢吡咯并环化合物及其应用 |
| TW202400149A (zh) | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
| US11919872B1 (en) | 2023-10-11 | 2024-03-05 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| US11912675B1 (en) | 2023-10-11 | 2024-02-27 | King Faisal University | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound |
| US11897850B1 (en) | 2023-10-11 | 2024-02-13 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound |
| US11891366B1 (en) | 2023-10-12 | 2024-02-06 | King Faisal University | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| CN119613393A (zh) * | 2024-11-13 | 2025-03-14 | 深圳华津生物科技有限公司 | Trpc5抑制剂及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1678609A (zh) * | 2002-08-30 | 2005-10-05 | 格吕伦塔尔有限公司 | 2－吡咯烷－2－基－[1,3,4]－噁二唑衍生物和其作为抗抑制药的用途 |
| WO2007039781A2 (en) * | 2005-10-05 | 2007-04-12 | Richter Gedeon Vegyészeti Gyár Rt. | New compounds |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
| DE60110066T2 (de) | 2000-06-16 | 2006-02-02 | Smithkline Beecham P.L.C., Brentford | Piperidine zur verwendung als orexinrezeptorantagonisten |
| US6943160B2 (en) | 2000-11-28 | 2005-09-13 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| EP1435955A2 (en) | 2001-05-05 | 2004-07-14 | SmithKline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| ES2299567T3 (es) | 2001-05-05 | 2008-06-01 | Smithkline Beecham Plc | N-aroilaminas ciclicas. |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| WO2003002561A1 (en) | 2001-06-28 | 2003-01-09 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| AU2003262516A1 (en) | 2002-09-18 | 2004-04-08 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| PE20050226A1 (es) | 2003-06-04 | 2005-05-18 | Aventis Pharma Sa | Productos aril-heteroaromaticos y composiciones que los contienen |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| KR100848747B1 (ko) | 2004-03-01 | 2008-07-25 | 액테리온 파마슈티칼 리미티드 | 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체 |
| WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
| EP1604989A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| US7269781B2 (en) | 2004-06-25 | 2007-09-11 | Hewlett-Packard Development Company, L.P. | Discrete universal denoising with reliability information |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| CA2644010A1 (en) | 2006-03-15 | 2007-09-20 | Actelion Pharmaceuticals Ltd | Tetrahydroisoquinoline derivatives to enhance memory function |
| AU2007272854B2 (en) | 2006-07-14 | 2013-08-01 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| WO2008011557A2 (en) * | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
| AU2007275301A1 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
| US7994336B2 (en) | 2006-08-15 | 2011-08-09 | Actelion Pharmaceuticals Ltd. | Azetidine compounds as orexin receptor antagonists |
| CA2662612A1 (en) | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
| WO2008065626A2 (en) | 2006-12-01 | 2008-06-05 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| AR064561A1 (es) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| ES2351079T3 (es) | 2007-05-14 | 2011-01-31 | Actelion Pharmaceuticals Ltd. | Derivados de 2-ciclopropil-tiazol. |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2152674B1 (en) | 2007-05-22 | 2011-08-03 | Boehringer Ingelheim International GmbH | Benzimidazolone chymase inhibitors |
| WO2008150364A1 (en) | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| AU2008257693B2 (en) | 2007-06-01 | 2011-01-27 | F. Hoffmann-La Roche Ag | Piperidine-amide derivatives |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| TW200911242A (en) | 2007-07-03 | 2009-03-16 | Glaxo Group Ltd | Novel compounds |
| EP2164847B1 (en) | 2007-07-03 | 2011-09-14 | Actelion Pharmaceuticals Ltd. | 3-aza-bicyclo[3.3.0]octane compounds |
| US7751938B2 (en) | 2007-07-05 | 2010-07-06 | Panasonic Corporation | Robot arm control device and control method, robot, and control program |
| CN101790515A (zh) | 2007-07-27 | 2010-07-28 | 埃科特莱茵药品有限公司 | 反式-3-氮杂-双环[3.1.0]己烷衍生物 |
| AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
| KR20100046047A (ko) | 2007-07-27 | 2010-05-04 | 액테리온 파마슈티칼 리미티드 | 2-아자-비시클로[3.3.0]옥탄 유도체 |
| CN101874030B (zh) | 2007-09-24 | 2012-11-14 | 埃科特莱茵药品有限公司 | 用作食欲素受体拮抗剂的吡咯烷和哌啶 |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| EP2225231B1 (en) | 2007-12-18 | 2011-08-17 | Actelion Pharmaceuticals Ltd. | Aminotriazole derivatives as alx agonists |
| RU2010138640A (ru) | 2008-02-21 | 2012-03-27 | Актелион Фармасьютиклз Лтд (Ch) | Производные 2-аза-бицикло [2.2.1] гептана |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| CA2729985A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
| WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| CA2739344A1 (en) | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| US8710076B2 (en) | 2008-10-21 | 2014-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| WO2010060470A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| EP2358712A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| AR074426A1 (es) | 2008-12-02 | 2011-01-19 | Glaxo Group Ltd | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende |
| TW201033190A (en) | 2008-12-02 | 2010-09-16 | Glaxo Group Ltd | Novel compounds |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| JP2012522794A (ja) | 2009-04-03 | 2012-09-27 | メルク・シャープ・エンド・ドーム・コーポレイション | レニン阻害薬 |
| KR20120007061A (ko) | 2009-04-24 | 2012-01-19 | 글락소 그룹 리미티드 | 오렉신 길항제로서 사용되는 3-아자비시클로［4.1.0］헵탄 |
| JP5095035B2 (ja) | 2009-06-09 | 2012-12-12 | アクテリオン ファーマシューティカルズ リミテッド | フッ素化アミノトリアゾール誘導体 |
| ES2735411T3 (es) | 2009-10-23 | 2019-12-18 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina |
| WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| JP5848251B2 (ja) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ．ベー． | オレキシン受容体調節因子としての縮合複素環式化合物 |
| US8735384B2 (en) | 2010-01-19 | 2014-05-27 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| CA2812699A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| KR101689093B1 (ko) | 2012-06-04 | 2016-12-22 | 액테리온 파마슈티칼 리미티드 | 벤즈이미다졸-프롤린 유도체 |
| WO2014141065A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
-
2013
- 2013-10-09 WO PCT/IB2013/059233 patent/WO2014057435A1/en not_active Ceased
- 2013-10-09 EP EP13805561.1A patent/EP2906553B1/en active Active
- 2013-10-09 EA EA201500399A patent/EA201500399A1/ru unknown
- 2013-10-09 KR KR1020157012089A patent/KR102151288B1/ko not_active Expired - Fee Related
- 2013-10-09 BR BR112015007516A patent/BR112015007516A2/pt not_active IP Right Cessation
- 2013-10-09 SG SG11201502493XA patent/SG11201502493XA/en unknown
- 2013-10-09 AR ARP130103661A patent/AR092955A1/es unknown
- 2013-10-09 JP JP2015536264A patent/JP6244365B2/ja not_active Expired - Fee Related
- 2013-10-09 CA CA2885180A patent/CA2885180C/en active Active
- 2013-10-09 MX MX2015004638A patent/MX2015004638A/es unknown
- 2013-10-09 AU AU2013328301A patent/AU2013328301A1/en not_active Abandoned
- 2013-10-09 CN CN201380051391.3A patent/CN104703980B/zh not_active Expired - Fee Related
- 2013-10-09 TW TW102136619A patent/TW201414727A/zh unknown
- 2013-10-09 US US14/434,997 patent/US9493446B2/en not_active Expired - Fee Related
-
2015
- 2015-03-20 PH PH12015500627A patent/PH12015500627A1/en unknown
- 2015-03-31 IL IL238052A patent/IL238052A0/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1678609A (zh) * | 2002-08-30 | 2005-10-05 | 格吕伦塔尔有限公司 | 2－吡咯烷－2－基－[1,3,4]－噁二唑衍生物和其作为抗抑制药的用途 |
| WO2007039781A2 (en) * | 2005-10-05 | 2007-04-12 | Richter Gedeon Vegyészeti Gyár Rt. | New compounds |
Non-Patent Citations (1)
| Title |
|---|
| Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists;Jeffrey P. Lamb,et al.;《Bioorganic & Medicinal Chemistry Letters》;20101203;2711-2714 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201414727A (zh) | 2014-04-16 |
| KR102151288B1 (ko) | 2020-09-03 |
| EP2906553A1 (en) | 2015-08-19 |
| PH12015500627A1 (en) | 2015-05-11 |
| US9493446B2 (en) | 2016-11-15 |
| WO2014057435A1 (en) | 2014-04-17 |
| CN104703980A (zh) | 2015-06-10 |
| BR112015007516A2 (pt) | 2017-07-04 |
| KR20150064753A (ko) | 2015-06-11 |
| AR092955A1 (es) | 2015-05-06 |
| CA2885180A1 (en) | 2014-04-17 |
| EA201500399A1 (ru) | 2015-09-30 |
| AU2013328301A8 (en) | 2015-06-11 |
| AU2013328301A1 (en) | 2015-05-28 |
| SG11201502493XA (en) | 2015-04-29 |
| JP6244365B2 (ja) | 2017-12-06 |
| MX2015004638A (es) | 2015-07-14 |
| IL238052A0 (en) | 2015-05-31 |
| CA2885180C (en) | 2021-03-02 |
| JP2015533157A (ja) | 2015-11-19 |
| US20150252032A1 (en) | 2015-09-10 |
| EP2906553B1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104703980B (zh) | 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂 | |
| US11040966B2 (en) | Benzimidazole-proline derivatives | |
| CN103917538B (zh) | 2-(1,2,3-三唑-2-基)苯甲酰胺及3-(1,2,3-三唑-2-基)吡啶酰胺衍生物 | |
| US11713312B2 (en) | Substituted bicyclic compounds as farnesoid X receptor modulators | |
| US9403813B2 (en) | Azetidine amide derivatives as orexin receptor antagonists | |
| EA047337B1 (ru) | Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора | |
| HK1208449B (en) | Benzimidazole-proline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171101 Address after: Swiss A Skei Weil Patentee after: ACTELION PHARMACEUTICALS LTD. Address before: Swiss A Skei Weil Patentee before: Actelion Pharmaceuticals Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170922 |